|
| Press Releases |
|
 |
|
| Wednesday, June 22, 2022 |
|
|
Eisai Publishes Potential Economic Value of Investigational Lecanemab in Peer-Reviewed Neurology and Therapy Journal |
| Eisai Co., Ltd. today announced publication of results from an early phase evaluation that aimed to estimate potential economic value of its investigational anti-amyloid-beta (Abeta) protofibril antibody lecanemab in people living with early Alzheimer's disease (AD) using a validated disease simulation model. more info >> |
|
| Monday, June 6, 2022 |
|
|
Eisai Presents New Findings for Antibody Drug Conjugate Farletuzumab Ecteribulin at 2022 ASCO Annual Meeting |
| Eisai Co., Ltd. announced today new investigational data from the platinum-resistant ovarian cancer (PROC) cohort expansion of a Phase 1 study (Study 101) evaluating the antibody drug conjugate (ADC) co-developed by Eisai and Bristol Myers Squibb, farletuzumab ecteribulin (MORAb-202). more info >> |
|
| Friday, June 3, 2022 |
|
|
Eisai to Present Latest Data on Lemborexant at The 36th Annual Sleep 2022 Meeting |
| Eisai Co., Ltd. announced a total of seven poster presentations including the latest data on its in-house discovered orexin receptor antagonist lemborexant (product name: DAYVIGO) will be given at the 36th annual meeting of the Associated Professional Sleep Societies (SLEEP 2022), to be held from June 4 to 8, 2022, in Charlotte, NC, the United States. more info >> |
|
| Friday, May 27, 2022 |
|
|
Eisai Contributes to the Science of Cancer Medicine at ASCO 2022 |
| Eisai Co., Ltd. announced today the presentation of research across various types of cancer from its oncology portfolio during the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting (#ASCO22), which is taking place virtually and in-person in Chicago from June 3 to 7. more info >> |
|
|
Eisai: MHLW Grants Orphan Drug Designation in Japan to Mecobalamin Ultrahigh-Dose Formulation with Prospective Indication for Delaying the Progression of Disease and Functional Impairment of ALS |
| Eisai Co., Ltd. announced today that it has received orphan drug designation for ultrahigh-dose mecobalamin, with a prospective indication for delaying the progression of disease and functional impairment of amyotrophic lateral sclerosis (ALS), by the Ministry of Health, Labour and Welfare (MHLW). more info >> |
|
| Tuesday, May 10, 2022 |
|
|
Eisai Completes Rolling Submission to the U.S. FDA for Biologics License Application of Lecanemab for Early Alzheimer's Disease Under the Accelerated Approval Pathway |
| Eisai Co., Ltd. and Biogen Inc. announced today that Eisai has completed the rolling submission to the U.S. Food and Drug Administration (FDA) of a Biologics License Application (BLA) under the accelerated approval pathway. more info >> |
|
|
Eisai Initiates Preparation for New Drug Application, Based on the Results of an Investigator-Initiated Clinical Trial of Ultrahigh-Dose Mecobalamin for Amyotrophic Lateral Sclerosis in Japan |
| Eisai Co., Ltd. today announced that it has initiated preparation on a New Drug Application for ultrahigh-dose mecobalamin. more info >> |
|
| Friday, April 1, 2022 |
|
|
Eisai Announces Acquisition of Arteryex Shares (Making Arteryex a Subsidiary) to Strengthen and Rapidly Expand the Foundation of its Digital Solution Business |
| Eisai Co., Ltd. announced today that Eisai has acquired a majority of the shares issued by Arteryex Inc., a company that plans and develops software related to digital solutions such as provision of medical information platforms, through purchase of shares and subscription of a third-party allocation of common shares, and made it a subsidiary, as of March 31, 2022. more info >> |
|
| Monday, March 28, 2022 |
|
|
Eisai: Announcement About an Approval for Additional Indication of Jyseleca, JAK inhibitor |
| Gilead Sciences K.K., Eisai Co., Ltd. and EA Pharma Co., Ltd. announced that Gilead acquired an approval of additional indication of Jyseleca, Janus Kinase (JAK) inhibitor, for the treatment of patients with active moderate-to-severe ulcerative colitis in Japan. more info >> |
|
| Tuesday, March 22, 2022 |
|
|
Eisai: Latest Findings on Lecanemab Presented at AD/PD 2022 Annual Meeting |
| Eisai Co., Ltd. and Biogen Inc. announced today that the latest findings on lecanemab, an investigational anti-amyloid-beta (Abeta) protofibril antibody being developed for the treatment of early Alzheimer's disease (AD), were presented at the Abeta Targeted Therapies in AD 2 Symposium at the 2022 International Conference on Alzheimer's and Parkinson's Diseases (AD/PD) March 15-20 in Barcelona, Spain and virtually. more info >> |
|
|
|
|
|
|
|
|
 |
| Latest Press Releases |
|
TANAKA's New Head Office, TANAKA Building Received The GOOD DESIGN AWARD 2025 
Nov 7, 2025 4:00 JST
|
|
|
Honda Unveils Next-generation Technologies at "Honda Automotive Technology Workshop" for Electrified Models to be Launched in Second Half of 2020s
Nov 6, 2025 22:44 JST
|
|
|
Market Value Lower Than Cash Assets? It's Time to Reevaluate NIVF
Nov 6, 2025 21:36 HKT/SGT
|
|
|
Winvest Group Announces Strategic Partnership with Greater Bay Area RWA Incubator; Southeast Asia Headquarters to Be Established in Malaysia
Nov 6, 2025 21:30 HKT/SGT
|
|
|
K.Wah Group Supports 2025 Legislative Council Election
Nov 6, 2025 21:09 HKT/SGT
|
|
|
Ten organizations have jointly launched a project titled "Development of Integrated Simulation Platform for Sustainable and Competitive Maritime Industry"
Nov 6, 2025 22:00 JST
|
|
|
Fujitsu to develop new chatbot for Japan Pension Service
Nov 6, 2025 21:24 JST
|
|
|
The 17th Hong Kong International Wine & Spirits Fair Opens Today
Nov 6, 2025 19:16 HKT/SGT
|
|
|
Stripe and NEC to Provide Face Recognition Payment Service via Stripe Terminal
Nov 6, 2025 17:30 JST
|
|
|
Excent Capital Announces Swap-Free Trading on All U.S. Stocks and Indices
Nov 6, 2025 16:00 HKT/SGT
|
|
|
ESA, MediaTek, Eutelsat, Airbus, Sharp, ITRI, and R&S Announce World's First Rel-19 5G-Advanced NR-NTN Connection over OneWeb LEO Satellites
Nov 6, 2025 17:00 JST
|
|
|
Hybrid Dump Truck Demonstration Test at South African Mining Site Selected by UNIDO's Industrial Cooperation Programme
Nov 6, 2025 16:16 JST
|
|
|
Mitsubishi Power Receives Contract to Upgrade Existing Boiler Equipment at the O Mon 1 Thermal Power Plant in Vietnam
Nov 6, 2025 16:01 JST
|
|
|
Tune Talk partners with Truecaller to Enhance Customer Experience and Trust Across Malaysia's Telecom Sector
Nov 6, 2025 15:00 HKT/SGT
|
|
|
MHI and ICM Form Strategic Alliance to Advance Ethanol Dehydration Efficiency
Nov 6, 2025 15:38 JST
|
|
|
|
|
More Press release >> |
|
|
|
|
|
|
|
